Results Demonstrate Potential for Givosiran as a Treatment for Acute Hepatic Porphyria
October 1st 2018Results from the interim analysis of the ENVISION phase 3 trial shows that givosiran treatment was associated with a statistically significant reduction in urinarly ALA levels in patients with acute intermittent porphyria.
Read More